Pricing Log in Create free account
Monday 9 November 2026 Export ORMP’s income statement to Excel — free account

Oramed Pharmaceuticals Inc.

ORMP

Healthcare Biotechnology

Oramed Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 49.3% from fiscal 2023.

Revenue
+193.3%
EPS
+493.8%
Free cash flow
+94.3%

Quarter to June 2026, against a year earlier

3.86 0.03 −0.77%
Market cap
$160.6M
P/E
0.9×
Fwd P/E
0.9×
Dividend yield
6.48%
F-score
n/a
ROIC
−3.40%
Net debt / EBITDA
8.4×
Dividend safety
45/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Net sold
$1.2M
Trades
4 sells · 0 buys
Ownership
23.7%

Capital & Financial Ratios $m

Size
Market Cap 161
Revenue ttm 4
Net income ttm 175
Free cash flow ttm (5)
Net debt Q (51)
Valuation
P/E 0.9
Forward P/E 0.9
Price / sales 39.4 (above 10: high)
Forward P/S Powerpack
Price / FCF n/m
Price / book 0.5
Financial health
Current ratio Q 5.0 (at or above 1.5: strong)
Debt / equity Q n/m
Interest coverage Q (12.0)
Growth
Revenue growth Q +193.3% (above 0%: growing)
Operating income growth Q −11.1% (below 0%: shrinking)
EPS, this year +246.5% (at or above 15%: strong)
EPS, next year A +50.0% (at or above 15%: strong)
Revenue, next year A −25.4% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates; n/m is not meaningful, as a P/E on a loss. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 26.8×, against a ten-year median of 16.4×; over the ten years it ranged from −37.4× in 2023 to 263× in 2021.
P/S against its own 10 years 53.48%
10-year low 10-year high
P/B against its own 10 years 1.17%
10-year low 10-year high
EV/Sales against its own 10 years 46.05%
10-year low 10-year high

Dividends

Yield
6.48%
Annual rate
0.25
Payout ratio
6.07%
  1. 0.25 ’26
paid change on the year, %

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 162 142 126 51
Receivables — — — 1
Inventory — — — —
Other — — — —
163 143 133 53
2023 2024 2025 Q'26
Payables 2 5 7 9
ST’ Debt — — — —
Other — — — —
53 6 19 11

Compound Annual Growth %

10y 5y 3y
Sales 12.05% (5.85%) (9.55%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 26.37% 3.69% 9.74%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.43 Actual −0.09

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY25 −0.04 −0.05 Miss by 0.01
Q3 FY25 −0.04 0.00 Beat by 0.04
Q4 FY25 0.00 −0.06 Miss by 0.06
Q2 FY26 0.43 −0.09 Miss by 0.52
Q3 FY26 0.43 — Reports 12 November 2026

EPS $

Mar Jun Sep Dec Year
’26 0.91 1.84 — — —
’25 (0.19) 0.31 1.13 0.24 1.50
’24 0.04 0.22 (0.48) (0.25) (0.48)
’23 (0.08) (0.03) (0.08) 0.33 0.14
’22 — — (0.18) (0.22) (0.94)
’22 (0.27) (0.27) — — (0.94)
’21 — — (0.21) (0.22) (0.33)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 2 — — — 2
’23 1 1 — — 1
’22 — — 1 1 3
’22 1 1 — — 3
’21 — — 1 1 1
’21 1 1 — — 3
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) 0 — — —
’25 (4) (4) (2) 0 (9)
’24 (1) 2 (7) (2) (8)
’23 (6) (3) (1) (1) (10)
’22 — — (2) (8) (28)
’22 (9) (8) — — (29)
’21 — — 1 3 (11)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) 0 — — —
’25 (4) (4) (2) 0 (9)
’24 (1) 2 (7) (2) (8)
’23 (6) (3) (1) (1) (11)
’22 — — (2) (8) (28)
’22 (9) (9) — — (29)
’21 — — 1 3 (11)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 1 2 2 3 3 1 3 1 — 2 4 +13.5% — — — —
Gross margin, % 23.56 92.39 103.51 96.67 100.00 100.00 100.00 100.00 — 0.65 32.31 (22.9) pt
EBT (10) (10) (13) (14) (12) (12) (38) 5 (16) 75 220 n/m
EBT margin, % (1,502.18) (410.42) (519.68) (519.98) (424.76) (1,355.64) (1,393.41) 379.70 0.00 3,766.20 0.00 +5,268.4 pt
Net income (11) (10) (13) (14) (12) (12) (38) 5 (19) 64 175 n/m
Per share, $
Per share, $ Revenue 0.05 0.18 0.16 0.15 0.13 0.02 0.07 0.03 0.00 0.05 0.00 (0.6%)
Earnings (0.87) (0.79) (0.86) (0.82) (0.56) (0.33) (0.94) 0.14 (0.48) 1.53 4.23 n/m
Cash flow 0.37 (0.44) (0.98) (0.74) (0.61) (0.30) (0.72) (0.26) (0.21) (0.22) (0.13) n/m
Capex 0.00 0.00 0.00 0.00 0.00 0.00 (0.01) (0.01) 0.00 0.00 0.00 (13.0%)
Free cash flow 0.37 (0.44) (0.99) (0.74) (0.61) (0.30) (0.73) (0.26) (0.21) (0.22) (0.13) n/m
Book value 2.07 1.45 2.09 1.11 1.60 4.49 3.88 4.04 3.56 4.82 7.74 +9.8%
Shares, m 13 13 15 17 21 37 39 40 41 41 41 +14.1%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 17.50 — 1.88 0.91 2.2
P/S 0.00 46.87 30.08 20.79 26.44 194.84 178.90 36.54 — 29.35 39.40 62.6
P/B 3.48 5.98 2.37 2.90 2.18 3.18 3.20 0.61 — 0.59 0.50 2.7
EV/Sales 0.00 38.67 17.64 8.85 11.72 141.06 121.29 (23.41) — (1.96) 26.81 34.9
EV/FCF 249.95 (11.67) (1.58) (0.89) (1.25) 78.17 (11.55) 6.00 — 0.86 (20.67) 34.2
Cash, $m
Cash, $m Operating cash flow 5 (6) (15) (13) (12) (11) (28) (10) (8) (9) (5) n/m
Capex 0 0 0 0 0 0 0 0 0 0 0 0.0%
Free cash flow 5 (6) (15) (13) (13) (11) (28) (11) (8) (9) (5) n/m
Balance, $m
Balance, $m Working capital 28 15 26 28 36 141 151 109 138 114 43 +17.1%
Net debt (31) (20) (30) (32) (40) (146) (156) (162) (142) (126) (51) +16.8%
Shareholders’ equity 26 19 31 19 33 167 151 163 145 200 317 +25.3%
Returns, %
Returns, % ROA (31.70) (25.70) (29.56) (34.99) (29.03) (7.63) (22.62) 2.89 (10.14) 32.76 65.52 +64.5 pt
ROIC 0.00 0.00 (1,302.68) 0.00 0.00 (37.89) 0.00 (1,164.97) (233.78) (12.77) (3.40) (12.8) pt
ROE (42.98) (46.14) (50.55) (56.85) (44.04) (8.24) (24.14) 3.52 (12.37) 36.65 73.90 +79.6 pt
People
People Employees 12 14 13 13 12 13 17 15 13 13 — +0.9%
Revenue/emp, $m 0.05 0.18 0.19 0.21 0.23 0.00 0.16 0.09 0.00 0.15 — +12.5%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2025 · fundamentals updated 2 Nov 2026

Oramed Pharmaceuticals Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MDWD MediWound Ltd. $184.0M — (loss-making) — (loss-making) −45.83% (below 0%: shrinking) n/m −49.90% (below 0%: shrinking) 10.90% (305.89%) Compare
WHWK Whitehawk Therapeutics, Inc. $178.4M — (loss-making) — (loss-making) +33.48% (above 0%: growing) n/m +72.57% (above 0%: growing) 89.36% 0.00% Compare
PEPG PepGen, Inc. $171.1M — (loss-making) — — n/m +33.02% (above 0%: growing) 0.00% 0.00% Compare
CNTN Canton Strategic Holdings, Inc. $164.1M — (loss-making) — — n/m −600.39% (below 0%: shrinking) 100.00% (80.37%) Compare
ZNTL Zentalis Pharmaceuticals, Inc. $162.8M — (loss-making) — (loss-making) — n/m −9.06% (below 0%: shrinking) 100.00% 0.00% Compare
IPHA Innate Pharma S.A. Sponsored ADR $160.9M — (loss-making) — +246.29% (above 0%: growing) +106.08% (above 0%: growing) −929.03% (below 0%: shrinking) 0.00% 0.00% Compare
ORMP Oramed Pharmaceuticals Inc. $160.6M 0.9× 0.9× +193.26% (above 0%: growing) +493.75% (above 0%: growing) +94.29% (above 0%: growing) 0.65% 0.00%
ALXO ALX Oncology Holdings Inc. $159.7M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m +31.65% (above 0%: growing) 0.00% 0.00% Compare
STRO Sutro Biopharma, Inc. $159.5M — (loss-making) — (loss-making) −84.57% (below 0%: shrinking) n/m +14.55% (above 0%: growing) 100.00% (303.77%) Compare
Median of peers $163.5M — — −45.83% — +2.74% 50.13% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 3 August 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 4.77m 4.80m 118.00
2024 2.10m 2.14m 105.00
2023 1.66m 265.81k 19.00

Ownership

Directors and executive officers, together 20.77%
Nadav Kidron#+ 8.21%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Oramed Pharmaceuticals Inc. (ORMP) Latest News

25 Jun

Impact 3 · · PR Newswire

18 Jun

Impact 3 ·

8 Jun

Impact 3 · · Zacks Small Cap Research

26 Mar

Impact 3 · · Associated Press Finance

25 Mar

Impact 4 · · GlobeNewswire

13 Mar

Impact 4 · · GlobeNewswire
Impact 3 · · Simply Wall St.

26 Feb

Impact 4 · · Zacks Small Cap Research

14 Jan

Impact 3 · · Simply Wall St.

13 Jan

Impact 4 · · GlobeNewswire
Impact 4 · · PR Newswire

7 Jan

Impact 3 · · PR Newswire

16 Dec

Impact 4 · · Simply Wall St.

24 Nov

Impact 4 · · Zacks Small Cap ResearchMotley FoolMT NewswiresMT Newswires

21 Nov

Impact 3 · · Simply Wall St.

17 Nov

Impact 3 · · PR NewswireAssociated Press FinanceSimply Wall St.GuruFocus.comZacksMT Newswires
Impact 3 · · PR Newswire

13 Nov

Impact 3 · · Associated Press Finance

28 Oct

Impact 3 · · Simply Wall St.

23 Oct

Impact 4 · · PR NewswireSimply Wall St.Simply Wall St.Simply Wall St.Clinical Trials ArenaSimply Wall St.Simply Wall St.Simply Wall St.

1 Oct

Impact 3 · · GlobeNewswireMT NewswiresMT NewswiresMT NewswiresBenzingaBenzingaMT NewswiresMT Newswires

14 Aug

Impact 3 · · Associated Press Finance

28 Jul

Impact 4 ·

27 Jun

Impact 3 ·

17 May

Impact 4 · · Simply Wall St.

28 Apr

Impact 4 ·
Impact 4 · · PR Newswire

3 Apr

Impact 4 ·

4 Mar

Impact 4 · · PR Newswire

11 Feb

Impact 3 ·
stockrow.com/ORMP · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com